Skip to main content
. 2018 Jul 18;4(3):24. doi: 10.3390/ijns4030024

Table 2.

Performance criteria of LSD newborn screening assays in the Missouri and Illinois public health laboratories.

GAA (Pompe) IDUA (MPS I) GLA (Fabry) GBA (Gaucher)
MO (DMF) IL (MS/MS) MO (DMF) IL (MS/MS) MO (DMF) IL (MS/MS) MO (DMF) IL (MS/MS)
Total infants 308,000 219,793 308,000 219,793 308,000 219,793 308,000 219,793
Screen Positives 161 139 133 151 179 107 37 117
Pending 0 8 0 24 0 16 0 19
Refused/Lost to f.u./Died 2 n/a 5 n/a 12 n/a 2 n/a
Normal 48 87 45 87 66 59 22 91
Carrier 39 15 8 5 0 0 5 0
Pseudodeficient 31 15 63 30 0 16 0 0
Undetermined /VUS/GUS 3 9 4 2 4 6 6 2 2
Confirmed Positive 32 10 2 1 94 10 5 5
PPV 1 26% 11% 3% 4% 60% 18% 21% 7%
False Positive rate 2 0.04% 0.05% 0.04% 0.06% 0.02% 0.03% 0.01% 0.04%
False positives per 100,000 38.3 53.2 37.7 55.5 21.4 34.1 8.8 41.4

1 Positive predictive value (PPV) calculated as [confirmed pos + VUS]/[screen pos + lost + refused + died]; 2 False positive rate (FPR) calculated as: normal + carrier + pseudo/total; 3 Undetermined/VUS/GUS includes samples with 1 pathogenic mutation + 1 VUS, 2 VUSs, or single VUS for Fabry. VUS: Variant of unknown significance; GUS: Genotype of unknown significance or onset.